Table 2.
The follow-up time for the 12 cases
| Case | Operation | Chemotherapy | Recurrence | PFS/month | Survival state | Follow-up/month |
| 1 | BSO/TAH/OM/LN | EP6 | No | 34 | NED | 34 |
| 2 | BSO/TAH/OM/LN | TC6 | No | 37 | NED | 37 |
| 3 | USO | EP7 | Yes, brain | 9 | DOD | 10 |
| 4 | BSO/TAH/OM/LN | EP6 | Yes, liver | 13 | AWD | 13 |
| 5 | BSO/OM /LN |
EP6 | Yes, bones | 17 | AWD | 25 |
| 6 | NACT+BSO/TAH/OM/LN | TC8 | Yes, pelvic | 13 | AWD | 15 |
| 7 | OM/PB | TC3 | Yes, pelvic | 3 | DOD | 10 |
| 8 | BSO/TAH/OM/LN | EP6 | No | 15 | NED | 26 |
| 9 | BSO/TAH/OM/LN | TP6 | Yes, lymph | 6 | AWD | 17 |
| 10 | BSO/TAH/OM/LN | TP6 +PARPi |
Yes, liver | 9 | AWD | 22 |
| 11 | BSO/TAH/OM/LN | TC6+ Radiotherapy |
No | 49 | NED | 49 |
| 12 | - | EP6 | Yes, pelvic | 6 | DOD | 9 |
EP: Etoposide/Cisplatin; TC: Paclitaxel/Carboplatin; TP: Paclitaxel/Cisplatin; DOD: Dead of disease; AWD: Alive with disease; NED: No evidence of disease; Om: Omentectomy; USO: Unilateral salpingo-oophorectomy; BSO: Bilateral salpingo-oophorectomy; LN: Lymph node dissection; PB: Peritoneal biopsy; NACT: Neoadjuvant chemotherapy.